Filter...

AnatomyDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesDisciplines and OccupationsInformation ScienceHealth CareGeographicals

Select a category...

EpoprostenolHypertension, PulmonaryAntihypertensive AgentsDrug StorageIloprostInfusions, IntravenousAdministration, IntravenousPulmonary Veno-Occlusive DiseaseHemodynamicsTolazolineExercise TolerancePreservatives, PharmaceuticalSulfonesHemangioma, CapillaryVasodilator AgentsHeart-Lung TransplantationPurinesVascular ResistancePulmonary CirculationSulfonamidesAcenocoumarolPulmonary ArteryPulmonary Wedge PressureDrug StabilityHeart Septal DefectsHypertension, PortalChemistry, PharmaceuticalInfusions, ParenteralTreatment OutcomeExcipientsLung TransplantationPiperazinesBlood PressureConnective Tissue DiseasesBleeding TimeProstaglandinsDrug Therapy, CombinationPlatelet AggregationCardiac OutputAdministration, InhalationFollow-Up StudiesInjections, IntravenousPlatelet Aggregation InhibitorsDose-Response Relationship, DrugIsoxazolesReceptors, EpoprostenolInfusions, Intra-ArterialDrug Administration ScheduleVentricular Function, RightDrug EvaluationAdenosine DiphosphateAnticoagulantsPulmonary EmbolismAdministration, OralAngiographyRetrospective StudiesJapanSurvival Rate

FlolanCatheter and infusion pumpIntravenousSodiumProstacyclinPulmonary and systemicVasodilatorProstaglandinsPlateletDizzinessDosageChronicCompoundsHypertensionSevereEffectsPatientsBlood pressureAdministrationCareWorkDirectAdditional

Flolan2

• The major actions of treprostinil appear to be similar to the effects of epoprostenol (Flolan® or Veletri®) and include vasodilatation of the pulmonary and systemic vascular beds (widening of narrowed blood vessels in the lung and other parts of the body) and inhibition of platelet aggregation (clumping). (patientworthy.com)
• Sterile Diluent for Flolan or Sterile Diluent for Epoprostenol), Sterile Water for Injection, or 0.9% Sodium Chloride Injection prior to administration. (rxlist.com)

Catheter and infusion pump1

• Intravenous therapy with VELETRI ® will likely be needed for prolonged periods, possibly years, so consider the patient's capacity to accept and care for a permanent intravenous catheter and infusion pump. (janssencarepath.com)

Intravenous1

• Prescribing information states that Veletri is taken as a continuous intravenous infusion through a thin, flexible tube called a Hickman or Groshong line. (myphteam.com)

Sodium1

• Reconstitute VELETRI ® only as directed using Sterile Water for Injection, USP, or Sodium Chloride 0.9% Injection, USP. (janssencarepath.com)

Prostacyclin2

• In some patients, chronic prostacyclin analogue therapy (epoprostenol) can be of benefit, particularly as a bridge to heart-lung transplantation. (medscape.com)
• VELETRI ® is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity. (janssencarepath.com)

Pulmonary and systemic2

• VELETRI ® is a potent pulmonary and systemic vasodilator. (janssencarepath.com)
• Epoprostenol has two major pharmacological actions: (1) direct vasodilation of pulmonary and systemic arterial vascular beds, and (2) inhibition of platelet aggregation. (lgmpharma.com)

Vasodilator1

• Epoprostenol is a strong vasodilator of all vascular beds. (medscape.com)

Prostaglandins1

• Epoprostenol (PGI2) is a member of the family of prostaglandins that is derived from arachidonic acid. (lgmpharma.com)

Platelet1

• The major pharmacological actions of epoprostenol is ultimately inhibition of platelet aggregation. (lgmpharma.com)

Dizziness3

• Veletri can also cause dizziness. (rxwiki.com)
• Because epoprostenol is metabolized rapidly, even brief interruptions in the delivery of VELETRI ® may result in symptoms associated with rebound pulmonary hypertension including dyspnea, dizziness, and asthenia. (janssencarepath.com)
• Abrupt withdrawal (including interruptions in drug delivery) or sudden large reductions in dosage of VELETRI ® may result in symptoms associated with rebound pulmonary hypertension, including dyspnea, dizziness, and asthenia. (janssencarepath.com)

Dosage1

• Dosage of VELETRI ® during chronic use should be adjusted at the first sign of recurrence or worsening of symptoms attributable to pulmonary hypertension or the occurrence of adverse events associated with epoprostenol. (janssencarepath.com)

Chronic1

• During chronic use, deliver VELETRI ® continuously on an ambulatory basis through a permanent indwelling central venous catheter. (janssencarepath.com)

Compounds1

• VELETRI ® is also contraindicated in patients with known hypersensitivity to the drug or to structurally related compounds. (janssencarepath.com)

Hypertension3

• Veletri is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to improve exercise capacity in cases of pulmonary arterial hypertension (PAH). (myphteam.com)
• Veletri is a prescription medication used to treat pulmonary arterial hypertension in order to improve exercise capacity. (rxwiki.com)
• VELETRI ® should be used only by clinicians experienced in the diagnosis and treatment of pulmonary hypertension. (janssencarepath.com)

Severe1

• VELETRI ® is contraindicated in patients with congestive heart failure due to severe left ventricular systolic dysfunction. (janssencarepath.com)

Effects5

• Rare but serious side effects listed for Veletri include hypotension (low blood pressure), pulmonary edema (swelling and fluid in the lungs), and bleeding. (myphteam.com)
• This is not a complete list of Veletri side effects. (rxwiki.com)
• Veletri can cause serious withdrawal side effects. (rxwiki.com)
• To avoid withdrawal side effects, do not suddenly stop taking Veletri. (rxwiki.com)
• Additional pharmacologic effects of epoprostenol in animals include bronchodilation, inhibition of gastric acid secretion, and decreased gastric emptying. (lgmpharma.com)

Patients3

• VELETRI ® should not be used chronically in patients who during dose initiation develop pulmonary edema, which may be associated with pulmonary veno-occlusive disease. (janssencarepath.com)
• Unless contraindicated, administer anticoagulant therapy to patients receiving VELETRI ® to reduce the risk of pulmonary thromboembolism or systemic embolism through a patent foramen ovale. (janssencarepath.com)
• In patients with PAH requiring transition from epoprostenol, Remodulin is indicated to diminish the rate of clinical deterioration. (rxlist.com)

Blood pressure1

• Veletri treats high blood pressure in the lungs. (rxwiki.com)

Administration3

• Veletri comes in the form of single-use vials that must be reconstituted before administration. (myphteam.com)
• Do not mix VELETRI ® with any other parenteral medications or solutions prior to or during administration. (janssencarepath.com)
• To reduce the risk of infection, use aseptic technique in the reconstitution and administration of VELETRI ® and in routine catheter care. (janssencarepath.com)

Care1

• Initiate VELETRI ® in a setting with adequate personnel and equipment for physiologic monitoring and emergency care. (janssencarepath.com)

Work1

• How well did Veletri work for you? (rxwiki.com)

Direct2

• Do not expose VELETRI ® to direct sunlight. (janssencarepath.com)
• At low doses, there is vagally mediated brudycardia, but at higher doses, epoprostenol causes reflex tachycardia in response to direct vasodilation and hypotension. (lgmpharma.com)

Additional1

• Fourteen additional minor metabolites have been isolated from urine, indicating that epoprostenol is extensively metabolized in humans. (lgmpharma.com)